BioNTech SE Sponsored ADR (BNTX) vs Royalty Pharma PLC (RPRX)
- BioNTech SE Sponsored ADR BNTX 87.57 −2.92%
- Royalty Pharma PLC RPRX 61.29 +2.80%
BioNTech SE Sponsored ADR and Royalty Pharma PLC are both Biotechnology companies. Royalty Pharma PLC is the larger, with a market value of $34.3B against $22.7B — 1.5× the size. BioNTech SE Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; Royalty Pharma PLC trades at 42.3×. Royalty Pharma PLC grew revenue faster over the last twelve months: 10.0% against −3.33%. Royalty Pharma PLC has the higher net margin (32.0% vs −65.8%) and the higher return on invested capital (5.28% vs −38.4%). Across the 20 metrics below, Royalty Pharma PLC leads on 13 and BioNTech SE Sponsored ADR on 7.
Valuation
Profitability
| Metric | BNTX | RPRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 75.24% | 100.00% | 65.16% |
| Operating margin | (77.94%) | 59.61% | 0.00% |
| Net margin | (65.75%) | 32.02% | 0.00% |
| Free cash flow margin | 16.58% | 51.66% | 0.00% |
| Return on equity | (9.53%) | 8.42% | (56.36%) |
| Return on assets | (8.24%) | 4.26% | (48.04%) |
| Return on invested capital | (38.39%) | 5.28% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack